Stock info IBA | Filter  Basic-Info

Stock: IBA (Bel mid), ISIN: BE0003766806

Last Price 12.12 Max Price 17.00
Min Price 8.39 1 Year return -20.47
Avg. Target 0.00 Expected Return -100.00 %
Sector Health Care Subsector Biotechnology
Sell 0 Rating
Hold 0 Concensus
Buy 0
Annual report 2018

IBA began its existence in 1986 as a spin-off of the Cyclotron Research Center of the Catholic University of Louvain-la-Neuve (UCL), which produced its first cyclotron in 1947. The objective was to exploit a unique expertise in particle accelerator technology to meet growing needs in the fields of medicine and industry. (ISIN: BE0003766806 / Mnemo: IBAB)

Loading...

IBA was founded by Yves Jongen in 1986 as a by-product of the Cyclotron Research Center of the Catholic University of Louvain-la-Neuve, which developed its primary cyclotron in 1947. The main purpose was to develop an exclusive proficiency in particle accelerator technology to meet uprising needs in medication and manufacturing business. Despite the fact that the company was originally lively in medical imaging, IBA rapidly acknowledged the need to diversify. So, the corporation turned its focus to radiotherapy (Proton Therapy) and developed cyclotrons which enables them to take care of several forms of cancer with a level of meticulousness and effectiveness. IBA builds up, develops and maintains medical devices and software resolution for cancer treatment by proton beam therapy, for cancer analysis and for patient eminence assurance (Dosimetry).



The corporate partners with foremost healthcare companies to offer cancer clinics and academic health centers with a completely incorporated approach of the patient flow. At present, IBA services in oncology are used in approximately 3,000 hospitals globally.
A company's ability in particle accelerators facilitates IBA to offer sterilization and ionization solutions also in the healthcare industry. IBA is headquartered in Belgium, IBA has operations in approximately more than 40 countries across North America, Europe & Asia. IBA is quoted on the pan-European stock exchange EURONEXT. IBA Molecular is a joint venture companionship between IBA and SK Capital Partners in which IBA has possession of a 40% stake.



IBA's mission is to look after, improve and save lives while conquesting over illness and improving health of each patient which is also the objective of every physician and the motivation for all researchers. IBA is having a zealous squad of professionals enthusiastic about developing innovative technologies to cure cancer which affects us all, either directly or indirectly. It takes more than improvement and Research & Development team to deliver primary edge technology for the advantage of the patients. It obliges for zeal and willpower to confront the conventional way of doing things. IBA challenges developing new technologies and strategies and shares thoughts and knowledge with its patrons and partners together with the foremost specialist to develop and distribute tailored solutions to produce enhanced results for the benefit of the patient. In 2012 IBA formed a tactical association with SK Capital Partners to make IBA Molecular Imaging, a jointly-owned companionship resulting from the IBA’s Molecular imaging unit. SK Capital Partners owns a 60 % stake in the company while IBA has the remaining 40%. The decisive objective of the Group is to provide solutions, products and services that will assist its patrons to shield, improve and save lives of people globally leveraging on its turf of knowledge and proficiency with enthusiasm and commitment.


Contact info:Country: BelgiumPhone: 32 2 229 66 82Email: info-worldwide@iba-group.comWebsite: www.iba.be

Sector Review IBA

Loading...
Year Turnover Total sector Market share
2019 283 141,925 0.20 %
2020 312 170,231 0.18 %
2021 313 252,886 0.12 %
2022 361 238,500 0.15 %
2023 0 0 0.00 %

Advice IBA

Date Label Bank Label Stock Label Advice Label Price Label Diff Label
March 22, 2024 ING IBA Hold 10.50 -15.43 %
February 13, 2024 KBC Securities IBA Buy 18.00 32.67 %
December 11, 2023 DeGroof Petercam IBA Buy 18.20 33.41 %
February 09, 2024 KBC Securities IBA Buy 18.00 32.67 %
March 24, 2023 ING IBA Hold 18.00 32.67 %
March 24, 2023 DeGroof Petercam IBA Buy 23.90 49.29 %
February 09, 2023 KBC Securities IBA Buy 20.50 50.83 %
December 16, 2022 Kepler Capital Markets IBA Buy 19.50 45.74 %
December 12, 2022 DeGroof Petercam IBA Buy 22.60 53.19 %
February 01, 2022 KBC Securities IBA Buy 17.50 5.26 %
November 21, 2021 KBC Securities IBA Hold 17.50 14.97 %
June 17, 2021 KBC Securities IBA Hold 17.50 13.49 %
May 20, 2021 KBC Securities IBA Hold 12.00 -33.17 %
April 08, 2021 Kepler Capital Markets IBA Buy 18.50 10.81 %
February 02, 2021 Jefferies & Co. IBA Sell 12.50 -32.00 %
January 22, 2021 DeGroof Petercam IBA Hold 15.00 -10.00 %
January 21, 2021 KBC Securities IBA Hold 12.00 -19.50 %
September 01, 2020 DeGroof Petercam IBA Hold 11.00 -57.27 %
August 27, 2020 KBC Securities IBA Hold 11.00 -48.91 %
May 13, 2020 KBC Securities IBA Hold 9.00 -83.56 %
March 26, 2020 KBC Securities IBA Hold 10.00 -50.40 %
March 11, 2020 Kepler Capital Markets IBA Hold 9.00 -58.89 %
January 28, 2020 KBC Securities IBA Buy 23.50 37.87 %
January 21, 2020 Jefferies & Co. IBA Sell 10.80 -31.30 %
November 19, 2019 Kepler Capital Markets IBA Hold 15.00 24.00 %
April 02, 2019 Jefferies & Co. IBA Hold 14.00 44.64 %
February 26, 2019 KBC Securities IBA Buy 23.50 55.96 %
January 24, 2019 DeGroof Petercam IBA Hold 13.00 22.77 %
January 11, 2019 Jefferies & Co. IBA Hold 13.10 6.03 %
August 30, 2018 DeGroof Petercam IBA Hold 22.00 25.55 %
August 24, 2018 Jefferies & Co. IBA Hold 25.00 32.00 %
May 29, 2018 KBC Securities IBA Buy 23.50 36.47 %
April 05, 2018 Jefferies & Co. IBA Hold 27.00 44.85 %
March 23, 2018 KBC Securities IBA Hold 20.00 33.62 %
January 05, 2018 DeGroof Petercam IBA Sell 14.90 18.39 %
January 05, 2018 KBC Securities IBA Hold 23.00 47.13 %
November 16, 2017 DeGroof Petercam IBA Hold 23.30 34.94 %
August 28, 2017 KBC Securities IBA Hold 26.00 19.27 %
August 24, 2017 KBC Securities IBA Hold 19.00 -11.26 %
August 24, 2017 DeGroof Petercam IBA Hold 27.00 21.70 %



News IBA

No Records Found

Annual reports IBA

2017 2018 2019 2020 2021

Profile IBA

IBA

(BE0003766806)/ IBAB

The company mostly operates in the biotech sector. The global biotech companies gained around 59 percent over the last 10 years. Since 2011 the sector is 70 percent higher and over the past year minus 59 percent.

The past year was a profitable year for the IBA investors

The period between December 2015 and December 2016 was a good period for the investors. The stock gained almost 19 percent. IBA' stock rose the past 5 years at around 698 percent. IBA's revenues between 2011 and 2015 were relatively stable and moved between 221,11 million euros and 270,36 million euros. IBA's net incomes between 2011 and 2015 were very volatile through the time and moved between -17,75 million euros and 61,26 million euros.

The Belgian company paid out dividends in the past 5 years. Over the past 5 years the stock delivered an average dividend return of 1,14 percent.

Healthy financed: not so much debt IBA

At the end of 2015 the biotech company's balance sheet equaled 395,35 million euros. 231,72 million euros (58,61 percent of the total balance sheet) was financed by debt. Last year the biotech company's price/earnings-ratio (PE) was around 7. So the investors valued the stock at 7 times 2015' earnings per share. Many analysts say that based on her price/earnings-ratio and dividend yield the Belgian stock can be seen as a value stock.

At the end of 2015 the biotech company's market size (her number of outstanding share times the stock price) equaled around 914,97 million euros. At the end of 2015 the Belgian company had around 27,96 million stocks listed.

All IBA's annual reports can be found here. More information about IBA can be found it's website. .


Results IBA

Results
2015
2016
2017
2018
2019
2020
Revenue
270
329
287
208
283
312
Costs
209
304
327
213
275
280
Profit
61
24
-39
-4
8
32
Margin of profit
22.63
7.44
-13.64
-2.11
2.69
10.23
ROI
37.40
16.26
-36.07
-4.27
6.83
22.51

Balance IBA

Balance
2015
2016
2017
2018
2019
2020
Equity
164
150
109
103
111
142
Debt
232
230
224
289
314
369
Total assets
395
381
333
392
425
511
Solvency
41.39
39.51
32.69
26.29
26.19
27.76
Cash
82
75
27
36
46
151
Cashflow
45
-17
-45
-19
49
100
Employees
1,100
1,400
1,518
1,451
0
Revenue per employee
0.25
0.23
0.19
0.14
0.0
Cashflow / Debt
0.20
-0.07
-0.20
-0.06
0.15
0.27

Details IBA

Details
2016
2017
2018
2019
2020
Price
33.90
41.64
23.89
12.84
13.04
Eps
0.83
-1.34
-0.15
0.26
1.07
Price/earnings-ratio
40.84
-31.07
-159.27
49.38
11.33
Dividend
0.20
0.0
0.0
0.05
0.14
Dividend %
0.59 %
0.00 %
0.00 %
0.39 %
1.16 %
Payout %
0.24
0.0
0.0
0.19
0.13
Book value
5.17
3.71
3.50
3.78
4.78
Market to book
0.15
0.09
0.15
0.29
0.39
Cashflow per stock
-0.59
-1.52
-0.63
1.65
3.39
Stocks
29
29
29
29
30
Market Cap
986.15
1.219.55
703.52
378.26
359.48

Dividend IBA


Price info IBA

Date
Price
22 Mar 2024
12.12
18 Mar 2024
11.40
15 Mar 2024
11.14
12 Mar 2024
11.22
11 Mar 2024
11.20
09 Mar 2024
11.20
07 Mar 2024
9.85
01 Mar 2024
9.34
29 Feb 2024
9.41
27 Feb 2024
9.44
22 Feb 2024
9.73
21 Feb 2024
10.00
20 Feb 2024
10.20
15 Feb 2024
10.56
14 Feb 2024
10.84
13 Feb 2024
10.36
09 Feb 2024
10.08
08 Feb 2024
10.08
07 Feb 2024
9.99
06 Feb 2024
10.16
05 Feb 2024
10.20
01 Feb 2024
10.56
31 Jan 2024
10.56
30 Jan 2024
10.66
27 Jan 2024
10.48
25 Jan 2024
10.50
24 Jan 2024
10.36
23 Jan 2024
10.46
16 Jan 2024
11.10
11 Jan 2024
11.24